Krebs Biochemicals & Industries Ltd. significantly trails its peers in all key financial metrics, showing no growth, negative valuation ratios, and no profitability measures. This positions it as a sector laggard with potential concerns about its financial health.

• • Krebs Biochemicals shows zero revenue growth and negative EPS, indicating poor performance.
• • Sun Pharmaceuticals leads in profitability with a PE of 87.59 and ROE of 16.13%.
• • Krebs has the lowest valuation metrics with a PBV of -1.11 and PE of -5.64, suggesting it is undervalued but also raises concerns about viability.